RxDoctor Payments Data

Mark Nyitray, DO

Internal Medicine · Hicksville, NYNPI 1467457689

Payments from drug & device makers

$5,494in general payments, 2019–2025

Across 188 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$598
  • Intercept Pharmaceuticals, Inc.$521
  • E.r. Squibb & Sons, L.L.C.$470
  • Ferring Pharmaceuticals Inc.$304
  • Nestle Healthcare Nutrition Inc.$275
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,484100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,494 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$194,253
Medicare patients
363
Services billed
1,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide14$12,659
Mesalamine ErMesalamine15$12,596
SutabSod Sulf/Pot Chloride/Mag Sulf60$9,560
Omeprazole231$2,336
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates23$1,248
Dicyclomine Hcl27$851
Famotidine46$830
Levothyroxine Sodium22$682
Pantoprazole Sodium40$660
Lansoprazole15$562
Metoprolol Succinate23$472
Rosuvastatin Calcium25$354
Atorvastatin Calcium32$231
Amlodipine Besylate37$220
Metformin Hcl20$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,513$12,65914 claims
Braintree Laboratories, Inc.Sutab$81$9,56060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hicksville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →